Valuation
- Market cap
- 291,531,000
- Revenue TTM
- $109,160,000
- Net income TTM
- $-9,580,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -8.78%
- Debt to equity
- 0.00
Trading
- Volume
- 802,900
- Avg volume
- 523,072
- Day's range
- $1.47 – $1.67
- Shares out
- 181,075,000
- Stochastic %K
- 14%
- Beta
- 1.67
- Analysts
- Strong Sell
- Price target
- $5.12
Company profile
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308,...
Show more
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 267 817 5790
- Website
- https://www.centurytx.com
- Address
- 25 North 38th Street, 11th Floor, Philadelphia, United States
Latest news
No headlines yet.
